Patents Assigned to Universitatsklinikum Freiburg
-
Patent number: 10786550Abstract: The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity.Type: GrantFiled: May 6, 2016Date of Patent: September 29, 2020Assignee: Universitatsklinikum FreiburgInventors: Gernot Zissel, Joachim Müller-Quernheim, Antje Prasse
-
Patent number: 10426511Abstract: A device for detaching parietal thrombi from a bodily vessel is described having a catheter including at least one catheter section with a catheter wall with at least one wall opening which passes completely through the catheter wall. The catheter wall along the least one catheter section is made of a resiliently deformable material in which the at least one wall opening includes a separating helical gap wound around the catheter wall at least in parts along the catheter section. A fixing device permits releasable fixing of the catheter on a bodily vessel so that the catheter can be converted, exclusively by an external mechanical constraint in the form of a torque acting torsionally on the catheter, from a state of smaller catheter outer diameter to a state of larger catheter outer diameter.Type: GrantFiled: October 21, 2013Date of Patent: October 1, 2019Assignee: UNIVERSITÄTSKLINIKUM FREIBURGInventor: Christoph Hehrlein
-
Patent number: 10420581Abstract: A device for detaching parietal thrombi from a blood vessel is disclosed, comprising a catheter including at least one catheter section, wherein an outer diameter of the at least one catheter section is changeable and at least one wall opening extends transversely through a wall of the at least one catheter section. The catheter wall along the at least one catheter section is a resilient and deformable material. The catheter is transformed from a smaller catheter outer diameter to a uniform larger catheter outer diameter by a resilient change in shape. A displacement body can be introduced into the at least one catheter section which is transformed in diameter to deform the catheter from the smaller catheter outer diameter to the larger outer diameter for capturing thrombus material.Type: GrantFiled: November 12, 2012Date of Patent: September 24, 2019Assignee: UNIVERSITATSKLINIKUM FREIBURGInventor: Christoph Hehrlein
-
Patent number: 10357537Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.Type: GrantFiled: October 30, 2018Date of Patent: July 23, 2019Assignees: Medizinische Universitat Wien, Universitatsklinikum FreiburgInventors: Christian Werner Gruber, Carsten Gruendemann
-
Patent number: 10259915Abstract: The present invention relates to substrates comprising a crosslinked network of covalently attached antimicrobial and/or antibiofouling polymers. The crosslinked network of antimicrobial and/or antibiofouling polymers acts highly efficiently against pathogens, e.g. bacteria and fungi. Both the antimicrobial and the antibiofouling cross-linked polymer networks are preferably better resistant to mechanical damage than simple surface-immobilized polymer monolayers. The antimicrobial and/or antibiofouling polymers of the crosslinked network are preferably obtained by ring opening metathesis polymerization (ROMP) and exhibit a molecular weight of preferably more than 30,000 or even 100,000 g mol?1. The crosslinked network of antimicrobial and/or antibiofouling polymers is preferably covalently attached to the surface of a substrate, e.g. an implant, a medical device, medical equipment or a (tissue-supporting) biomaterial, etc.Type: GrantFiled: March 8, 2013Date of Patent: April 16, 2019Assignees: UNIVERSITATSKLINIKUM FREIBURG, ALBERT-LUDWIGS-UNIVERSITAT FREIBURGInventors: Karen Lienkamp, Jakob Belardi, Peng Zou, Ali Al-Ahmad, Thorsten Steinberg, Pascal Tomakidi
-
Patent number: 10159710Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.Type: GrantFiled: August 23, 2016Date of Patent: December 25, 2018Assignees: Universitatsklinikum Freiburg, Medizinische Universitat WienInventors: Christian Werner Gruber, Carsten Gruendemann
-
Patent number: 9995807Abstract: In a control method and control unit to monitor a data acquisition of magnetic resonance image data of an imaging area located in a measurement volume of a magnetic resonance apparatus, an RF excitation pulse is radiated by an RF transmission/reception device of the magnetic resonance apparatus, raw data are acquired after a time after the radiated excitation pulse, by means of the RF transmission/reception device, and store the raw data, the raw data are transmitted to a monitoring unit and (a) through (c) are repeated while switching different gradients for spatial coding by readout of k-space corresponding to the imaging area along trajectories that are predetermined by the switched gradients, up to a termination criterion that is predetermined by the monitoring unit.Type: GrantFiled: September 4, 2014Date of Patent: June 12, 2018Assignees: Siemens Aktiengesellschaft, Universitatsklinikum FreiburgInventors: Guobin Li, Dominik Paul
-
Patent number: 9957544Abstract: The present invention relates to a device comprising a sample receiving appliance, a receiving appliance for test organisms, preferably for a suspension comprising test organisms, in particular for a bacterial suspension, and a jet pump appliance, wherein the jet pump appliance is, or can be brought, into active connection with the receiving appliance, and wherein the jet pump appliance is designed and installed in order, by means of a propellant medium having a higher pressure than atmospheric pressure at the location of installation of the device to spray test organisms in the form of an aerosol in the direction of the sample receiving installation, wherein the device has an installation for controlling a reproducible pressure of the propellant medium during the spraying of the test organisms and also the use of a device according to the invention.Type: GrantFiled: March 1, 2013Date of Patent: May 1, 2018Assignee: UNIVERSITATSKLINIKUM FREIBURGInventors: Thorsten Steinberg, Ali Al-Ahmad, Karen Lienkamp, Norbert Nanko
-
Patent number: 9808522Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.Type: GrantFiled: August 17, 2011Date of Patent: November 7, 2017Assignees: UNIVERSITATSKLINIKUM FREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
-
Patent number: 9796744Abstract: The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium.Type: GrantFiled: November 13, 2007Date of Patent: October 24, 2017Assignee: UNIVERSITÄTSKLINIKUM FREIBURGInventors: Johannes Hübner, Otto Holst, Christian Theilacker, Zbigniew Kaczynski
-
Patent number: 9453052Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.Type: GrantFiled: December 21, 2012Date of Patent: September 27, 2016Assignees: Universitatsklinikum Freiburg, Medizinische Universitat WienInventors: Christian Werner Gruber, Carsten Gruendemann
-
Patent number: 9290531Abstract: The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.Type: GrantFiled: February 17, 2012Date of Patent: March 22, 2016Assignee: UNIVERSITÄTSKLINIKUM FREIBURGInventors: Johannes Huebner, Andrea Huebner-Kropec, Jeroen Dirk Cornelis Codée, Gijsbert Arie Van Der Marel, Wouter Frederick Johan Hogendorf
-
Patent number: 9278097Abstract: The invention provides a medication for the prophylaxis and/or therapy against diseases or complications in connection with portal hypertension, particularly against bleeding complications.Type: GrantFiled: June 3, 2004Date of Patent: March 8, 2016Assignee: Universitatsklinikum FreiburgInventors: Wolfgang Kreisel, Peter Deibert
-
Patent number: 9238694Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.Type: GrantFiled: December 13, 2013Date of Patent: January 19, 2016Assignee: UNIVERSITÄTSKLINIKUM FREIBURGInventors: Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
-
Patent number: 9005622Abstract: The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection.Type: GrantFiled: January 19, 2010Date of Patent: April 14, 2015Assignees: Forschungszentrum Borstel, Universitätsklinikum FreiburgInventors: Johannes Hübner, Christian Theilacker, Otto Holst, Zbigniew Kaczynski
-
Publication number: 20150025168Abstract: The present invention relates to substrates comprising a crosslinked network of covalently attached antimicrobial and/or antibiofouling polymers. The crosslinked network of antimicrobial and/or antibiofouling polymers acts highly efficiently against pathogens, e.g. bacteria and fungi. Both the antimicrobial and the antibiofouling cross-linked polymer networks are preferably better resistant to mechanical damage than simple surface-immobilized polymer monolayers. The antimicrobial and/or antibiofouling polymers of the crosslinked network are preferably obtained by ring opening metathesis polymerization (ROMP) and exhibit a molecular weight of preferably more than 30,000 or even 100,000 g mol?1. The crosslinked network of antimicrobial and/or antibiofouling polymers is preferably covalently attached to the surface of a substrate, e.g. an implant, a medical device, medical equipment or a (tissue-supporting) biomaterial, etc.Type: ApplicationFiled: March 8, 2013Publication date: January 22, 2015Applicant: Universitatsklinikum FreiburgInventors: Karen Lienkamp, Jakob Belardi, Peng Zou, Ali Al-Ahmad, Thorsten Steinberg, Pascal Tomakidi
-
Patent number: 8835115Abstract: The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.Type: GrantFiled: July 13, 2007Date of Patent: September 16, 2014Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Universitätsklinikum FreiburgInventors: William D. Figg, Klaus Mross, Dirk Behringer, Alex Sparreboom, Tristan Sissung, Stephan Mielke
-
Publication number: 20140155583Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.Type: ApplicationFiled: December 13, 2013Publication date: June 5, 2014Applicant: UNIVERSITÄTSKLINIKUM FREIBURGInventors: Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
-
Patent number: 8741302Abstract: A medicament for the treatment or the prevention of a bacterial infection is disclosed which contains a polypeptide having a contiguous sequence of at least six amino acids of SEQ ID NO:1. Said polypeptide can be used for the preparation of a vaccine against an Enterococcus infection.Type: GrantFiled: April 26, 2010Date of Patent: June 3, 2014Assignee: Universitatsklinikum FreiburgInventors: Johannes Huebner, Andrea Kropec-Huebner, Irina Sava
-
Publication number: 20140147445Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.Type: ApplicationFiled: August 17, 2011Publication date: May 29, 2014Applicants: BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD., UNIVERSITATSKLINIKUM FREIBURGInventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter